#6 Sectors in Brief - Medical Devices

The medical device sector mirrors the strategic operational patterns found in drug discovery. Both industries navigate similar macrotrends, operate within highly regulated environments, and exhibit comparable market dynamics where large companies often de-risk innovation costs by acquiring promising smaller firms.

Given that I believe that I have a competitve edge in the biotech & healthcare industry due to my educational background and the compounding knowledge from researching pharmaceutical drug discovery, manufacturing, and packaging, it feels like a natural and logical progression to shift my focus to the medical device sector in my ongoing search for high-quality companies.

DISCLAIMER: This article is not a recommendation to buy or sell any financial instrument, the content is educational and my personal opinion. Each person has to make his own analysis. Any action or decision you take as a result of viewing this article is your sole responsibility.

Podcast Generated from the Write-up

To give you more options to enjoy the write-up I have used Google NotebookLM to generate a podcast of the present write-up that you can listen to while running, during your commute or whenever you like.

Support Independent Analysis

This newsletter will always be FREE! If you’d like to help sustain it, consider buying me a coffee. With your contribution I will cover any annual costs I might incur and search for alternatives to enhance the experience.

What Is a Medical Device?

Medical devices are tools, instruments, machines, implants, software, or materials used to diagnose, prevent, monitor, treat, or alleviate disease or disability in humans. Unlike medicines and drugs, medical devices achieve their effect primarily through physical or mechanical means, not by chemical or biological action.

According to regulators such as the FDA in the United States and the EU Medical Device Regulation (MDR) in Europe, medical devices are defined as any product intended for medical use that does not achieve its primary purpose through chemical action. These include devices used to diagnose or treat diseases and injuries, monitor a patient’s health condition, modify or support anatomical structures or physiological functions, sustain life, or deliver and assist in the administration of drugs.

Types of Medical Devices

The domain of medical devices is remarkably vast and heterogeneous, ranging from fundamental instruments such as tongue depressors to sophisticated robotic surgical systems. To understand the landscape clearly, medical devices can be classified based on three characteristics: intended use, risk class (regulatory classification)and technological complexity.

1. Intended Use

These devices are at the forefront of identifying, monitoring, or predicting medical conditions. They provide critical insights into a patient's health status, enabling early detection, accurate diagnosis, and effective treatment planning. Their core purpose is to gather information about the body.

Divided by intended use, the main categories are:

• Diagnosis devices

  Equipment used to identify or detect medical conditions, diseases, or abnormalities in patients.

• Therapeutic Devices

  Instruments designed to treat, cure, or alleviate symptoms of diseases or medical conditions.

• Surgical Devices

  Tools and instruments specifically designed for use during surgical procedures to cut, dissect, manipulate, or repair tissues and organs.

• Assistive and Rehabilitative Devices

  Products that help individuals with disabilities or recovering from injury to improve their functional capabilities, mobility, or independence.

• Monitoring & Wearables

  Devices that continuously or periodically measure and display physiological data, often worn on the body for health tracking or medical oversight.

• Sterilization & Disinfection Equipment

  Systems employed to eliminate or reduce the presence of harmful microorganisms on medical instruments and surfaces to prevent infection.

2. Regulatory Risk Class

Different regions use different risk-based classification systems, which impact the level of scrutiny and documentation required. The main two classifications are the US FDA Classes and EU MDR Classes which classes are very much harmonized between them.

• Class I (Low Risk)

  These devices present the lowest potential risk to the user. They are generally simple in design and have a well-understood function. Most Class I devices are exempt from premarket notification (also known as a 510(k)), meaning manufacturers typically don't need to submit an application to the FDA before marketing the device.

• Class II (Moderate Risk)

  Class II devices pose a moderate risk to the user. While they are more complex than Class I devices, their risks can typically be controlled through established performance standards and specific labeling requirements. Most Class II devices require 510(k) clearance or the De Novo pathway before they can be marketed. A 510(k) submission demonstrates that the new device is substantially equivalent to a legally marketed predicate device, while the De Novo pathway is for novel low-to-moderate risk devices that have no predicate.

• Class III (High Risk)

  These devices are the most complex and present the highest potential risk to the user. They are often life-sustaining, life-supporting, or implanted, and their failure could result in serious injury or death. Class III devices require Premarket Approval (PMA) from the FDA before they can be marketed. A PMA is the most stringent type of device marketing application and requires extensive scientific evidence demonstrating the device's safety and effectiveness.

3. Technological Complexity

In addition to classification by risk, medical devices can also be grouped by their technological complexity or the innovation area they belong to. Here's an expansion of these modern groupings:

• Digital Health Devices

  This category encompasses devices and software that leverage information and communication technologies to improve health and healthcare. They often involve data collection, analysis, and delivery to support diagnostics, treatment, and patient management.

• Connected Devices (Internet of Medical Things - IoMT)

  This category focuses on devices that are interconnected, allowing for data exchange and remote monitoring. IoMT integrates medical devices with information technology, enabling real-time data collection and remote management of patient health.

• Combination Products

  These are therapeutic and diagnostic products that combine a drug, device, and/or biological product. Their regulation is complex as they fall under the purview of multiple regulatory bodies.

  The most common case are drug-device combos like prefilled auto-injectors, insulin pens, inhalers, or patches: These products integrate a drug substance with a delivery mechanism.

• Minimally Invasive Technologies

  These technologies aim to reduce the size of incisions, trauma, and recovery time associated with medical procedures, often leading to better patient outcomes.

• Robotic and Navigation Systems

  This category involves advanced systems that enhance precision, control, and visualization during surgical and interventional procedures, often leading to improved accuracy and reduced human error.

Key Differences with the Pharmaceutical Sector

There are four areas in which key differences between both sectors can be noted:

Legislation & Regulation

Despite similarities in overall regulatory burden, the specific legislative and regulatory pathways differ significantly. The medical device sector utilizes a risk-based classification system (Classes I, II, III), where the level of risk dictates the regulatory burden.

Device design often allows for more iterative improvements and shorter development timelines, with changes potentially introduced post-market, and clinical data requirements can be less extensive for lower-risk devices (e.g., 510(k) clearance based on substantial equivalence). In Europe, many devices are approved through Notified Bodies (third-party organizations designated to carry out conformity assessment according to a directive).

Conversely, the drug discovery sector follows a more rigid, multi-phase clinical trial process (Phases I, II, III, IV), which is typically longer and more expensive, with extensive pre-clinical and clinical data required before market approval. There is less emphasis on post-market iteration in terms of product modification (though new indications can be sought), and placebo-controlled trials are common. Drugs are reviewed directly by national or EU regulatory authorities like the FDA in the US or EMA in the EU.

Macrotrends

Despite market growth being driven by the same macrotrends, some of them manifest differently. Cybersecurity is a critical focus due to device connectivity and direct patient data handling, leading to strict compliance requirements to prevent device malfunction and data breaches. While data privacy is crucial for both, the focus in drug discovery is more on the vast datasets generated in trials and R&D, rather than real-time device-patient interaction.

Market Dynamics

Both sectors share fundamental market dynamics, characterized by high R&D costs, long development cycles for complex products, significant capital investment requirements, and increasing global market competition. Both also face challenges related to intellectual property protection.

Nevertheless, key differences exist in their market dynamics. Pricing transparency can be less opaque for high-end medical devices, with pricing often negotiated directly with hospital systems and group purchasing organizations (GPOs). Some medical device models are shifting towards usage-based or subscription fees, particularly in digital health. Sales and marketing efforts often target healthcare providers (physicians, hospitals) directly, with clinical evidence and ease of integration into existing workflows being critical for adoption.

In contrast, the drug discovery sector faces significant and growing pressure on drug pricing from governments, payers, and public opinion, especially for high-cost novel therapies (e.g., the Inflation Reduction Act in the US). Revenue is primarily driven by prescription volume and market share for approved drugs. While physicians influence prescribing, marketing and adoption are heavily influenced by formulary coverage from payers and increasing patient advocacy and awareness.

Intellectual Property (IP)

While patents are crucial in both industries, there's a notable difference in IP protection. In medical devices, patents are essential, but device designs can sometimes be more easily "designed around" compared to the unique chemical structures of drugs. Patents may cover the basic principle, with specific devices having multiple design variations that can circumvent existing patents. For drug discovery, strong patent protection plus data exclusivity are in place.

Data exclusivity protects the clinical trial data generated for a specific molecule, significantly increasing the time and cost for other companies. This is because, even if a competitor discovers a way to manufacture the same molecule, they're prohibited from using the original innovator's clinical trial data to support their own regulatory submissions. This necessitates independent clinical trials, which in turn grants the original innovator substantial market exclusivity.

Sectorial Trends

The medical devices industry's evolution is driven by the same core megatrends shaping the broader healthcare sector: an aging population in developed countries, the expanding middle class in emerging economies, and the growing prevalence of chronic diseases linked to modern lifestyles.

Furthermore, the medical devices sector is subject to its own set of powerful, specific trends that are both shaping its landscape and driving its growth.

Sustainability of Healthcare Expenditure

While emerging economies are increasing their healthcare expenditures, developed markets already dedicate substantial portions of their GDP to healthcare. High-income countries like the UK, Germany, and Japan typically spend between 10-13% of their GDP, with the US leading significantly, allocating over 16% to healthcare expenses.

Consequently technologies that permit the access to untapped value drivers and support treating patients efficiently while reducing operational costs are being implemented across the whole healthcare value chain, especially when referring to medical devices.

Efficiency focus within medical devices is especially relevant due to:

1. Their product-centric nature

   They are tangible and concrete compared to the mapping and optimization of complex administrative systems like hospital administrative flows or insurance schemes.

2. Their outcomes are easily measurable

   Detection improvement, surgical intervention durations, etc. are KPIs easily measurable to track progress and continuous efficiency improvement.

3. Innovation pace

   Compared to other segments of the industry, iteration cycles in the medical device industry are shorter, bringing better solutions to the market faster.

Remote Patient Monitoring (RPM) devices allow healthcare providers to monitor patients' vital signs and adherence from afar, reducing hospital readmissions and improving chronic disease management.

Digitalization and Integration

At the core of this growth is rapid innovation across fields such as AI, IoT, robotics, and advanced materials, leading to the development of highly precise and capable medical devices. This relentless innovation fundamentally underpins the burgeoning Digital Health Devices sector, where software and seamless connectivity are profoundly transforming healthcare delivery.

Within Digital Health, several specific advancements are particularly noteworthy:

• AI and Machine Learning Integration is dramatically enhancing diagnostic accuracy, automating routine tasks, improving outcome prediction, and enabling highly personalized treatment plans.

• The rise of Digital Therapeutics (DTx) offers software-based interventions that deliver evidence-backed therapeutic care for a variety of conditions.

• Software as a Medical Device (SaMD) represents a significant and expanding area for standalone medical software.

• Continued expansion in Mobile Health (mHealth) applications is boosting healthcare accessibility and convenience for patients.

Patient Centric Design

The medical device industry is experiencing a significant boom driven by a clear shift towards a patient-centric focus. This growing emphasis is fueling demand for user-friendly, home-based medical devices, which improve patient outcomes and offer cost savings by reducing hospital visits and optimizing healthcare workloads.

Moreover, minimally invasive technologies are revolutionizing medical procedures by using smaller incisions, leading to less pain, reduced recovery times, and minimal scarring for patients. These advancements enhance precision and outcomes through the integration of smaller, smarter instruments, often incorporating robotics, AI, and advanced imaging.

Regulatory Trends

Evolving global medical device regulations, characterized by increased scrutiny and reliance on Real-World Evidence (RWE), paradoxically favor market growth. While heightened oversight ensures safer, higher-quality devices, building trust among healthcare providers and payers. The crucial role of RWE, gathered significantly by medical devices themselves, streamlines regulatory approvals and incentivizes innovation, accelerating market access for effective technologies and fostering a dynamic, data-driven industry.

Market Outlook

Forecasts for the global medical device market's compound annual growth rate (CAGR) in the coming years vary, typically ranging from 4.5% to 9.5%. What remains consistent across these projections is that its growth is expected to outpace the global GDP CAGR.

Given my interest in industrial businesses, I will focus on medical device manufacturers. Exhibit 3 illustrates that the U.S. medical device manufacturing market alone is projected to grow by 5.9% over the next five years, according to GVR data.

These favorable growth prospects are underpinned by several aforementioned megatrends, including cost-effective patient monitoring and the increasing prevalence of chronic diseases. Beyond these, specific sub-segments also benefit from distinct market dynamics:

• Growing patient preference for wearable medical technology

  Faster innovation cycles among the medical device sector allowed for rapid improvement of these products through incremental innovations.

• Larger number of tests per patients

  The continuous development of superior and more effective tests directly encourages higher patient uptake. This trend is amplified by concurrent advancements in preventive medicine and increased public awareness. Moreover, this dynamic receives a substantial boost from Point-of-Care Testing (POCT), as these diagnostic devices facilitate testing closer to the patient, providing rapid results and enabling more immediate medical interventions. This proximity to care proves especially vital in underserved or remote regions.

• Expansion of biologics and vaccines over traditional drugs

  Many advanced biologics and vaccines require specialized delivery devices, driving the combination product market, for their precise patient dosing, such as GLP-1 pens and insulin pumps.

• Increased amount of accidents linked to screen time increase

  Increased screen time has been linked to a rise in accidents, such as falls, because it can worsen our attention span and negatively impact sleep quality. These factors contribute to a higher risk of injuries.

Challenges Ahead

The medical device sector, while vital, presents a complex web of risks spanning evolving regulations, market dynamics, IP protection, and sustainability concerns. A clear grasp of these areas is crucial for success.

Regulatory and Policy Risks

This category encompasses the challenges and uncertainties arising from the evolving landscape of laws, guidelines, and governmental decisions that directly impact the medical device industry.

• Evolving Digital Regulatory Frameworks

  The rapid rise of Software as a Medical Device (SaMD) and the integration of AI/ML into medical devices are driving significant shifts in regulatory frameworks. Regulators are actively developing new guidelines for SaMD, addressing unique challenges like continuous software updates, robust cybersecurity, and the transparency of underlying algorithms. Similarly, for AI/ML-powered devices, frameworks are emerging to manage adaptive models, ensuring transparency, mitigating bias, validating dynamic systems, and guaranteeing continuous safety, though the inherent uncertainty of these evolving standards poses risks of costly market delays for innovators.

  Furthermore, as medical devices become increasingly connected, stringent cybersecurity regulations are being globally enforced (e.g., FDA Guidance, EU MDR). Companies face the ongoing risk and cost of continually adapting to these evolving standards to safeguard patient data, device functionality, and prevent malicious attacks.

• Reimbursement Policies

  Changes in how healthcare systems, insurance providers, or government programs decide to pay for medical devices can significantly impact market access and profitability. Unfavorable reimbursement policies, delays in coverage decisions, or reduced payment rates pose a substantial financial risk to manufacturers, making it harder to recoup development costs and generate revenue.

• Global Harmonization Efforts

  While generally positive in the long term, the ongoing push for greater alignment of medical device regulations across different countries (e.g., through initiatives like IMDRF) can present short-term risks. Companies must navigate the transition periods and potential differences in interpretation as new harmonized standards are adopted, which can require significant adjustments to their regulatory strategies and documentation.

Market and Competitive Risks

The rise of trade protectionist policies, such as tariffs, import quotas, or local content requirements, can significantly disrupt global supply chains, increase manufacturing costs, and restrict market access for medical device companies operating internationally. Moreover, the harmonization efforts might be abandoned if collaboration between countries is stop due to geopolitical tensions.

Intellectual Property and Innovation Risks

The ability to secure and enforce strong intellectual property (IP) protection (patents, trademarks, trade secrets) is paramount in the medical device sector due to high R&D costs. A lack of clear IP protection or challenges in enforcing existing rights can lead to market erosion from competitors. Furthermore, the speed of innovation in this sector is critical; companies face the risk of being outpaced by competitors if they cannot rapidly develop and bring new, improved devices to market. This dynamic interplay between robust IP and swift innovation is essential for sustained success.

References

1. Investing in Health Care: The Threat & Opportunity of The Decade Ahead, https://intrinsicinvesting.com/2017/01/19/investing-in-health-care-the-threat-opportunity-of-the-decade-ahead/ 

2. Understading Medical Devices: Types, Regualtions, and Impact on Healthcare, https://www.meridian-medical.com/key-factors-influencing-medical-device-manufacturing-costs/

3. Association between excessive screen time and falls, with additional risk from insufficient sleep duration in children and adolescents, a large cross-sectional study in China, https://pmc.ncbi.nlm.nih.gov/articles/PMC11659216/ 

4. Medical Devices Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com/industry-reports/medical-devices-market-100085

My investment process always begins with a comprehensive understanding of the sector, so I've been dedicating significant time to learning its nuances, trends, and key players. This foundational knowledge is crucial before I even begin to evaluate individual companies. I've been thoroughly researching the medical devices sector lately, as my next deep dive is focused on a company within this industry.

Hope you enjoyed this earning review of Pandora. So please leave a comment, give it a like and share!

If you would like to receive new posts and support this type of content… do not hesitate, subscribe!